Your session is about to expire
← Back to Search
Molecular Breast Imaging for Breast Cancer
N/A
Waitlist Available
Led By Gaiane M. Rauch, MD, PHD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Has biopsy-proven invasive breast cancer (BI-RADS 6) and scheduled for neoadjuvant chemotherapy (NAC)
Newly diagnosed biopsy proven locoregional invasive breast cancer at MD Anderson Cancer Center, or referred to MD Anderson for treatment after initial radiologic (mammographic, sonographic, etc.) exams at an outside institution in whom NAC is planned
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
Study Summary
This trial looks at using technetium Tc-99m sestamibi to see if it can predict how well patients with breast cancer that has spread to nearby tissues will respond to chemotherapy.
Who is the study for?
This trial is for women over 18 with newly diagnosed invasive breast cancer that hasn't spread beyond the local area and who are scheduled for chemotherapy. They must not be pregnant, nursing, or allergic to Tc99m sestamibi.Check my eligibility
What is being tested?
The study tests if a special imaging technique using technetium Tc-99m sestamibi can predict how well patients respond to pre-surgery chemotherapy in treating locoregional breast cancer.See study design
What are the potential side effects?
While the document doesn't list specific side effects of Tc99m sestamibi MBI, common ones may include discomfort from the imaging procedure and rare allergic reactions to the tracer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have invasive breast cancer confirmed by biopsy and am scheduled for chemotherapy before surgery.
Select...
I have been newly diagnosed with invasive breast cancer and am planning to receive neoadjuvant chemotherapy.
Select...
My breast cancer is at stage T1-T4, may have spread to nearby lymph nodes but not to distant parts of the body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Detection of Treatment Response using Molecular Breast Imaging (MBI) plus Tc99m sestamibi
Trial Design
1Treatment groups
Experimental Treatment
Group I: Molecular Breast Imaging (MBI) + Tc99m sestamibiExperimental Treatment2 Interventions
Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,976 Previous Clinical Trials
1,789,412 Total Patients Enrolled
147 Trials studying Breast Cancer
63,190 Patients Enrolled for Breast Cancer
Gaiane M. Rauch, MD, PHDPrincipal InvestigatorM.D. Anderson Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My breast cancer is at stage T1-T4, may have spread to nearby lymph nodes but not to distant parts of the body.I am younger than 18 years old.You are allergic to Tc99m sestamibi.My cancer has spread to my chest wall.I am a woman aged 18 or older.I have invasive breast cancer confirmed by biopsy and am scheduled for chemotherapy before surgery.I have been newly diagnosed with invasive breast cancer and am planning to receive neoadjuvant chemotherapy.
Research Study Groups:
This trial has the following groups:- Group 1: Molecular Breast Imaging (MBI) + Tc99m sestamibi
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Could you provide the enrollment count for this experiment?
"This trial is no longer recruiting, as its most recent update was on September 13th 2022. Nevertheless, it may be useful to search for other studies; at present there are 2602 trials looking for individuals with breast cancer and 3 clinical trials seeking patients diagnosed with Tc99m sestamibi."
Answered by AI
Are participants still being sought for this research project?
"This clinical trial is now closed to recruitment. It was first posted in June of 2015 and its last edit occured on September 13th, 2022. Alternatively, there are currently 2602 trials for breast cancer and 3 trials involving Tc99m sestamibi that are open to applicants."
Answered by AI
Are there any existing investigations that involve the utilization of Tc99m sestamibi?
"At this time, there are 3 clinical trials involving Tc99m sestamibi in process; none have reached the third phase. Most of these studies take place at medical centres located in Houston, Texas but 8 other sites also participate."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger